Malaria Clinical Trial
Official title:
A Phase I/IIa Sporozoite Challenge Study to Assess the Safety, Immunogenicity and Protective Efficacy of Intravenous Boosting With Malaria Vaccine Candidates ChAd63 and MVA Encoding ME-TRAP
Plasmodium falciparum Malaria remains a major global health problem with approximately 200
million cases and 500,000 deaths worldwide annually, mostly in African infants. Current
malarial control strategies are threatened by emergence of parasite resistance to drug
treatment and resistance of the mosquito vector to certain insecticides. A deployable malaria
vaccine is therefore a key strategy for reducing malaria mortality and progressing towards
global eradication, but those in clinical trials are currently someway short of WHO targets.
ChAd63 ME-TRAP and MVA ME-TRAP are leading candidate vaccines being developed by Adrian
Hill's group at the University of Oxford, and collaborators. Since 2007, testing of these
vaccines intramuscularly in over 900 volunteers has shown them to be safe, well tolerated and
capable of delivering partial efficacy against malaria infection. This study will be the
first time studying the efficacy of giving a boosting dose of the vaccines intravenously in
what the investigators call a "prime-target" strategy. It follows very encouraging
pre-clinical work showing this route can target desirable immune responses to the liver to
fight a crucial stage of malaria infection. An ongoing recent phase I study is dose
escalating both these vaccines intravenously as a single dose prior to commencing this trial
where intramuscular and intravenous doses will be combined for the first time. The
investigators will initially recruit 46 healthy UK adult volunteers who will be enrolled into
4 vaccination arms (10 volunteers each) and an unvaccinated control group (6 volunteers) who
will undergo a controlled human malaria infection (CHMI). These are standardised, carefully
supervised infection experiments used internationally to assess vaccine efficacy. As this is
the first time giving intramuscular and intravenous doses of these vaccines in a combined
schedule, the investigators will closely profile the safety and immune response during the
vaccination follow-up. All trial activity will take place in Oxford.
The study is considered of low risk to the health of participants. Volunteers will receive
investigational vaccines, be infected with malaria by mosquito bite, may develop clinical
malaria disease, will be treated with antimalarial drugs, and will have blood taken
regularly. They will also be given the option to undergo a minimally invasive procedure -
Fine Needle Aspiration of the liver - to examine the immune response in this target organ
which is also considered to be low risk.
As this is the first time intravenous dose of the vaccines following intramuscular
prime/boost doses will be administered, once volunteers have received their intramuscular
doses the investigators will stagger the intravenous vaccinations to allow for interim safety
reviews. The first volunteer in groups 1&2, once they have received their two intramuscular
doses, will receive their intravenous vaccine dose alone and observed for a minimum 8 hours.
If there have been no concerns identified at the 8 hour and 24 hour reviews identified by the
CI and Local Safety Committee (LSC) chair, the next two volunteers in these groups will
receive their intravenous vaccine dose. There will be a further safety 24 hours after these
volunteers have been vaccinated before the remaining volunteers are vaccinated.
Volunteers are expected to have both vaccine site reactions (eg, pain, swelling, warmth in
the arm where the vaccine is given) and systemic reactions to vaccination (eg, fever,
headache, tiredness, sore muscles and joints). These are expected to resolve completely
within several days, and symptoms strong enough to prevent usual activities over this time
are expected to be uncommon.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |